Applied Genetic Technologies Corp (AGTC) SEC Filing 10-Q Quarterly report for the period ending Monday, December 31, 2018

Applied Genetic Technologies Corp

CIK: 1273636 Ticker: AGTC

Exhibit 99.1


AGTC Announces Financial Results and Business Update for the Quarter Ended December 31, 2018

GAINESVILLE, Fla., and CAMBRIDGE, Mass., February 7, 2019 – Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced financial results for the quarter ended December 31, 2018.

“AGTC is positioned for significant progress in 2019, including data readouts from our achromatopsia B3, achromatopsia A3 and X-linked retinitis pigmentosa clinical trials,” said Sue Washer, President and CEO of AGTC. “We also expect that our optogenetics partner, Bionic Sight, will file an Investigational New Drug application with the U.S. Food and Drug Administration in the first half of 2019. This diverse pipeline, combined with our strong financial position, affords us multiple opportunities to advance new approaches for patients experiencing vision loss that today have few or no treatment options.”

AGTC Clinical Program Update

AGTC continues to enhance its clinical infrastructure resulting in the acceleration of clinical enrollment in all the Company’s ongoing clinical trials. These resources have allowed AGTC to expand patient recruitment efforts, introduce new clinical trial sites, conduct surgical training and enhance clinical site support.

X-linked Retinitis Pigmentosa (XLRP) Phase 1/2 Clinical Trial

AGTC completed enrollment of the nine patients in the dose escalation portion of the Phase 1/2 clinical trial of its product candidate for XLRP in December and has also treated three patients in the expansion group of the Phase 1/2 clinical trial. The Company expects to:



Complete enrollment in the expansion group of the trial in the first quarter of 2019;



Provide interim six-month data on the dose escalation portion of the trial in the third quarter of 2019; and



Provide interim six-month data on the expansion group portion of the trial in the fourth quarter of 2019.



The following information was filed by Applied Genetic Technologies Corp (AGTC) on Thursday, February 7, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Applied Genetic Technologies Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Applied Genetic Technologies Corp.


Assess how Applied Genetic Technologies Corp's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Applied Genetic Technologies Corp's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors




Learn More
Bullish Bearish Neutral
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
Cash Flow
Inside Applied Genetic Technologies Corp's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Balance Sheets (Unaudited)
Condensed Balance Sheets (Unaudited) (Parenthetical)
Condensed Statement Of Stockholders' Equity (Unaudited)
Condensed Statements Of Cash Flows (Unaudited)
Condensed Statements Of Operations (Unaudited)
Collaboration Agreement
Collaboration Agreement (Tables)
Collaboration Agreement - Components Of Collaboration Revenue (Detail)
Collaboration Agreement - Summary Of Performance Obligations And Transaction Price (Detail)
Collaboration Agreements - Additional Information (Detail)
Collaboration Agreements - Summary Of Changes In Contract Assets And Liabilities (Detail)
Fair Value Of Financial Instruments And Investments
Fair Value Of Financial Instruments And Investments (Tables)
Fair Value Of Financial Instruments And Investments - Schedule Of Major Category Of Company's Financial Assets And Liabilities Measured At Fair Value On Recurring Basis (Detail)
Investments (Tables)
Investments - Summary Of Amortized Cost And Fair Value Of Held-To-Maturity Debt Securities (Detail)
Investments - Summary Of Company's Debt Securities Held-To-Maturity (Detail)
Investments - Summary Of Company's Investments (Detail)
Organization And Operations
Organization And Operations - Additional Information (Detail)
Share-Based Compensation Plans
Share-Based Compensation Plans (Tables)
Share-Based Compensation Plans - Additional Information (Detail)
Share-Based Compensation Plans - Stock Option Pricing Model Assumption (Detail)
Share-Based Compensation Plans - Summary Of Stock Option Activity (Detail)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Summary Of Significant Accounting Policies:
Summary Of Significant Accounting Policies: (Policies)

Material Contracts, Statements, Certifications & more

Applied Genetic Technologies Corp provided additional information to their SEC Filing as exhibits

Ticker: AGTC
CIK: 1273636
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-19-030848
Submitted to the SEC: Thu Feb 07 2019 11:06:34 AM EST
Accepted by the SEC: Thu Feb 07 2019
Period: Monday, December 31, 2018
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: